-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Non-alcoholic fatty liver disease (NAFLD) isan important link in metabolic syndromefrom non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH) .
Non-alcoholic fatty liver disease (NAFLD) Non-alcoholic fatty liver disease (NAFLD) Non-alcoholic fatty liver (NAFL) Non-alcoholic fatty liver (NAFL) Non-alcoholic steatohepatitis (NASH) Non-alcoholic fatty liver Hepatitis (NASH) There are currently no approved specific drugs for the treatment of NASH.
Breviscapine Breviscapine Natural Flavonoid Prescription Medicine Natural Flavonoid Prescription Medicine
A recent study published in Hepatology , a journal of hepatology , used in vivo and in vitro experiments , through histopathological observation, serum biochemical detection (TG, TC), western blotting experiment (adipogenic genes FASN and PPARγ), RNA sequencing, protein Omic analysis, etc.
Hepatology Hepatology in vivo and in vitro experiments in vivo and in vitro experiments
The results showed that breviscapine treatment significantly reduced lipid accumulation, inflammatory cell infiltration, liver damage and fiber in high-fat diet (HFD), high-fat/high cholesterol diet (HFHC) or methionine and choline-deficient diet (MCD) mice
Reducing the reduced lipid accumulation, inflammatory cell infiltration, liver injury and fibrosis lipid accumulation, inflammatory cell infiltration, liver injury and fibrosis key mechanism is inhibition of phosphorylation of TAK1 key mechanism of inhibition of the phosphorylation of TAK1 selective inhibitors 5Z-7- oxozeaenol selective inhibitor 5Z-7-oxozeaenol
These results indicate that breviscapine prevents the progression of NASH induced by metabolic stress by directly inhibiting TAK1 signaling
Literature source:
Literature source:Lan, T.
Lan, T.
, Jiang, S.
, Zhang, J.
, Weng, Q.
, Yu, Y.
, Li, H.
, Tian, S.
, Ding, X.
, Hu, S.
, Yang, Y.
, Wang, W.
, Wang, L.
, Luo, D.
, Xiao, X.
, Piao, S.
, Zhu, Q.
, Rong, X.
, & Guo, J.
(2021).
Breviscapine Alleviates Nonalcoholic Steatohepatitis by Inhibiting TGF-β-activated Kinase 1-dependent Signaling.
Hepatology (Baltimore, Md.
), 10.
1002/hep.
32221.
Advance online publication.
https://doi.
org/10.
1002/hep.
32221
Leave a message here
